Friday, January 28, 2022

New study: 133x risk of myocarditis after COVID vaccination

A recent study published on January 25, 2022, on JAMA Network, has shown that the risk of myocarditis following mRNA COVID vaccination is around 133 times greater than the background risk in the population.

The study, conducted by researchers from the U.S. Centers for Disease Control as well as from several U.S. universities and hospitals, examined the effects of vaccination with products manufactured by Pfizer-BioNTech and Moderna.

1626 cases of myocarditis were studied, and the results showed that the Pfizer-BioNTech product was most associated with higher risk, with 105.9 cases per million doses after the second vaccine shot in the 16 to 17 age group for males, and 70.7 cases per million doses after the second shot in the 12 to 15 age group for males.

At the time of data review, two reports of death in people younger than 30 years of age with potential myocarditis still remained under investigation and were not included in the case counts.

The study's authors noted that myocarditis following vaccination appeared to resolve more swiftly than in typical viral cases; however, given that vaccination is no longer considered a reliable way in which to avoid COVID infection, it is unclear whether this has any specific relevance to the cost-benefit analysis of COVID vaccination, especially considering the low risk of complications following coronavirus infection for the age group most at risk for heart-related complications following vaccination.

Given the plethora of studies confirming a link between vaccination and myocarditis, the CDC has commenced active surveillance of adolescents and young adults to monitor their progress following heart-related incidents after vaccination.

In conclusion, the study's authors note that myocarditis is a "Rare but serious adverse event that can occur after mRNA-based COVID-19 vaccination [and that] the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men. This risk should be considered in the context of the benefits of COVID-19 vaccination."

https://www.israelnationalnews.com/news/321238 

No comments: